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ABSTRACT 
 
Hamstring muscle and tendon injuries are commonly seen in sports medicine 
clinics, especially in track and field athletes. However, a less common subset of 
these injuries has recently begun to gain more attention among researchers and 
clinicians and is referred to as high hamstring tendinopathy. Patients suffering 
from this condition typically report deep buttock pain brought on by running, or 
in severe cases even by prolonged sitting, such as in driving a car for long 
periods of time. Diagnosis of this condition requires a specific patient history, 
positive signs on physical exams, as well as positive findings on imaging studies, 
primarily MRI and ultrasound. Treatment for high hamstring tendinopathy 
typically starts with conservative measures for pain management including ice, 
electrical stimulation, and pulsed ultrasound. As soon as patients are able, a 
physical therapy protocol is prescribed involving stretching, along with 
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strengthening, progressing to eccentric exercises. In cases where symptoms are 
persistent, more aggressive treatments can be followed, such as corticosteroid 
injections, extracorporeal shockwave therapy, and surgery in more severe cases. 
However, because these therapies are often ineffective, expensive, and 
potentially carry high risks, physicians have begun to turn to alternative forms of 
therapy. One such treatment gaining recent popularity is the use of platelet-rich 
plasma injections (PRP).  
 
The widely held belief is that PRP provides a higher than average concentration 
of growth factors than is normally contained in platelets and that these stimulate 
the wound healing cascade and help in tissue repair and regeneration. PRP is 
prepared using autologous whole blood from patients by two rounds of 
centrifugation, separating and concentrating the platelets from other components 
such as red blood cells and leukocytes.  
 
Although PRP has shown potential in treating musculoskeletal injuries such as 
chronic patellar tendinosis and chronic elbow tendinosis there has only been one 
study mentioning the injection of PRP for treating chronic high hamstring 
tendinopathy. This paper seeks to investigate the therapeutic efficacy of PRP in 
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treating these injuries by following the progress of patients receiving PRP 
injections over a 12-week period. Subjects were selected using specific inclusion 
and exclusion criteria from patients electing to receive the treatment. After 
providing informed consent, patients were evaluated using a baseline evaluation 
form and Lower Extremity Functional Scale questionnaire before receiving a 
single, ultrasound guided percutaneous injection. Patients were then required to 
follow a specific physical therapy protocol and return for follow-up evaluation 
12 weeks post-treatment using the same questionnaires.  
 
A majority of patients reported significant improvement in their symptoms with 
some reporting complete resolution of pain in certain activities. However, due to 
the small patient population, these results were not statistically significant. 
Future research in this area should include a larger population, more objective 
measures of improvement, and a randomized, controlled study. Although 
promising, the use of PRP injections in treating high hamstring tendinopathy 
requires further evidence in order to be a widely accepted form of treatment.  
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BACKGROUND 
 
Hamstring Anatomy and Histology:  
The hamstring muscles consist of the semitendinosus, the semimembranosus, 
and the biceps femoris, along with their corresponding tendons (Figure 1) 
(Clanton & Coupe, 1998). All muscles with exception of the short head of the 
biceps femoris originate at the ischial tuberosity at the bottom of the pelvis. The 
muscles separate into each individual components approximately 5-10 cm from 
the tuberosity, the first being the semimembranosus, running along the medial 
side of the femur. Semimembranosus has multiple insertions at the 
posteromedial corner of the knee, primarily at the posterior tubercle of the 
medial femoral condyle (Clanton & Coupe, 1998; Sutton, 1984). Both the 
semitendinosus and the long head of the biceps femoris originate at the 
inferomedial aspect of the ischial tuberosity (Clanton & Coupe, 1998; Sutton, 
1984). The second point of origin for the semitendinosus is an aponeurosis of the 
semitendinosus and long head of the biceps femoris distal to the ischial 
tuberosity. The tendon then runs over the tibial collateral ligament, forming part 
of the pes anserine and inserts behind the attachment of the sartorius below the 
gracilis onto the proximal medial surface of the tibia. The short head of the biceps 
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femoris has three origins: the lateral tip of the linea aspera, the lateral 
supracondylar line, and the lateral intermuscular septum. Eventually, the long 
and short head muscle fibers combine to form a tendon that inserts at the fibular 
head and the lateral tibial condyle (Clanton & Coupe, 1998; Sutton, 1984) (Figure 
2).  
 
Figure 1: Illustration of Basic Hamstring Anatomy. Figure downloaded from AAOS 
(http://orthoinfo.aaos.org/topic.cfm?topic=a00408#Anatomy. 
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Figure 2: MRI of Normal Hamstring Muscles and Ischial Tuberosity  
Three different MRI viewings of the hip (Coronal T1W (A), axial STIR (B), and sagittal T1W (C)) 
illustrating the normal ischial tuberosity along with the attachments at the origin of the long head 
of the biceps femoris, the semitendinosus, and the semimembranosus. Figure taken from Beltran 
et al., 2012 
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The histology of the muscles shows a possible explanation for its predisposition 
to overuse injury (Garrett, Califf, & Bassett, 1984). The hamstrings have more 
type 2 muscle fibers relative to other muscles in the lower extremity, suggesting 
their potential for high intrinsic tension forces. Combined with the fact that 
running increases the time the muscles are at maximal stretch, the hamstrings are 
at an increased risk for injuries (Garrett et al., 1984).  
 
High Hamstring Tendinopathy:  
High hamstring tendinopathy is an uncommon overuse injury mostly seen in 
middle to long distance runners (Fredericson et al., 2005). It has been described 
in the literature since 1988, although it was originally termed “hamstring 
syndrome” (Puranen & Orava, 1988). However, its presence has been receiving 
more attention as an important cause for chronic pain in the lower extremities 
and researchers have altered the nomenclature due to ambiguity of diagnosis in 
the previous terms (Lempainen et al., 2009; Puranen & Orava, 1988; Zissen et al., 
2010).  
 
 
 
5 
 
Diagnosis 
Patient history, physical examination, and imaging studies play key parts to the 
accurate diagnosis of this condition. The clinical triad for tendinopathy includes 
pain, swelling, and a reduced load bearing capacity (De Vos et al., 2010). Patients 
with high hamstring tendinopathy typically report deep buttock pain brought on 
by running, and in more severe cases the pain can be present during prolonged 
sitting (Puranen & Orava, 1988).  Physical examination for high hamstring 
tendinopathy is generally notable for local tenderness to palpation, pain with 
stretching, and reduced muscle activation. The tuberosity and the proximal 
hamstrings are palpated for signs of tenderness or thickening of the area 
(Fredericson et al., 2005). Tightness is assessed using the bent-knee stretch test 
(Figure 3), and the supine plank test is used to assess strength of the proximal 
hamstring (Figure 4) (Fredericson et al., 2005).
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Figure 3: Dr. Michael Fredericson performing bent knee stretch test. Figure taken from 
Fredericson et al., 2005 
 
 
 
 
 
Figure 4:  The supine plank test is used to assess strength of the hamstrings. Figure taken from  
Fredericson et al., 2005 
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Positive results on the three tests (tenderness to palpation, positive bent knee 
stretch and supine plank) are suggestive of an active high hamstring injury  
(Fredericson et al., 2005).   
 
Radiographic studies play an important part in the diagnosis. Plain film 
radiographs may demonstrate ischial tuberosity cortical irregularity, ectopic 
calcifications, bony avulsions, or evidence of sacroiliitis, but are often of limited 
use unless an avulsion fracture or extensive strain with obvious clinical swelling 
is present (Clanton & Coupe, 1998).  MRI (magnetic resonance imaging) is much 
more useful for the diagnosis of high hamstring tendinopathy as it can grade the 
extent of the injury and explore other potential causes for the patient’s symptoms 
(Zissen et al., 2010). The presence of increased signal on T1-weighted images 
without significant abnormality on fat-suppressed T2-weighted images is 
diagnostic for high hamstring tendinopathy (Fredericson et al., 2005) (Figure 5). 
There may also be stress reaction or bone edema within the ischial tuberosity, or 
the abnormal tendon findings such as focal partial tears (Fredericson et al., 2005) 
(Figure 6).  
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Figure 5: Patient with proximal hamstring tendinopathy.  
An MRI (A) and Ultrasound image (B) showings findings consistent with tendinopathy. Using 
Axial T2-weighting and fat-suppression the image reveals increased T2 signal at the origin of the 
tendon (arrowhead), characteristic of tendinopathy. In B, hypoechogenicity and heterogeneity 
(arrows) of the hamstring tendon can be seen (t) at the ischial tuberosity (it). Figure taken from  
Zissen et al., 2010  
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Figure 6:  A man, 45-years old with proximal hamstring injury and bone marrow edema. Axial 
T2-weighted fat-suppressed image showing bone marrow edema (arrows) within the ischial 
tuberosity. Irregularities of the adjacent hamstring tendons can also be seen. Figure taken from 
Zissen et al., 2010 
 
 
In addition to radiographs and MRI, high resolution ultrasound imaging is 
gaining acceptance because of lower cost, increased patient comfort, and the 
ability to examine the tissue in real-time. Ultrasound provides superior soft 
tissue resolution and characterization, particularly for highly organized tissues 
such as tendons and ligaments. Normal tendons and ligaments appear  
hyperechoic with linear fibrillar pattern under ultrasound on longitudinal 
images, whereas tendinopathic tendons appear hypoechoic due to the loss of 
organized collagen fiber. The tendon may also appear thickened due to the 
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presence of edema from ongoing inflammatory processes (Fullerton, 2008). With 
the increased use of ultrasound and MRI on patients with hamstring injuries, 
physicians are more able to diagnose the source of the pain and to focus 
treatments specifically to the injured muscle (Zissen et al., 2010). Both MRI and 
ultrasound can aid viewing of the effects of PRP on the targeted tissue and could 
be used in other research studies to record changes in tissue morphology and 
structure after PRP therapy (Lee et al., 2011).  
 
Treatment  
Conservative management for pain control is typically initiated with physical 
therapy modalities such as ice, electrical muscle stimulation, and pulsed 
ultrasound. Unlike acute injuries, non-steroidal anti-inflammatory drugs 
(NSAID’s) are ineffective in treating chronic tendinopathies (Brukner & Khan, 
2011). Correction of biomechanical factors such as pelvic alignment and soft 
tissue mobilization are also helpful, and the patient is encouraged to begin a 
progressive strengthening program as soon as possible. Hamstring strength 
training, especially eccentric exercises, is currently the best-supported treatment 
for hamstring muscle injuries. Eccentric strengthening helps to prevent tendency 
of developing shorter, inflexible muscles after injury, and can prepare the 
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rehabilitating muscle for the greater forces involved in sports (Sherry & Best, 
2004). Exercises progress from bilateral non-weight bearing to unilateral closed 
chain isometrics and isotonic open-chain exercises when bilateral exercises can 
be completed with no pain (Fredericson et al., 2005). Typically, conservatively 
managed hamstring injuries are fully resolved in 2-6 months, but in about 20% of 
patients, symptoms may persist for more than 6 months and require more 
aggressive treatment methods (Zissen et al., 2010), in which cases, injections of 
corticosteroids, extracorporeal shockwave therapy, and surgery may be 
recommended.  
Corticosteroid Injections 
A corticosteroid injection is recommended when other pain management 
techniques have been unsuccessful, especially in cases of edema surrounding the 
ischial tuberosity combined with a relatively normal looking tendon. However, 
steroid injections are not a long-term solution to chronic tendinopathies and is 
generally prescribed in conjunction with physical therapy regiments to augment 
the treatment (Fredericson et al., 2005).  
Extracorporeal shock-wave therapy (ESWT) 
Extracorporeal shock-wave therapy is a therapeutic technique originally used in 
nephrolithiasis treatments, but has become a successful treatment for other 
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chronic issues such as plantar fasciitis, patellar tendinopathy, and calcific 
tendinitis of the shoulder (Wang, 2012).  The mechanism behind the ESWT is not 
completely understood but it is thought that shockwaves can cause interstitial 
and extracellular effects, leading to improved tissue regeneration (Wang, 2012) 
Randomized controlled studies have shown its effectiveness in treating chronic 
tendinopathies (Al-Abbad & Simon, 2013; Galasso, Amelio, Riccelli, & Gasparini, 
2012) including one study suggesting that ESWT was more effective than 
conservative management in treating chronic proximal hamstring tendinopathy 
(Standaert, 2012).   
Surgery 
Surgery should be considered when conservative managements have failed to 
relieve symptoms of hamstring tendinopathy. Indications include recalcitrant, 
significant symptoms leading to functional and athletic limitations, and clinical 
and MRI findings consistent with proximal hamstring tendinopathy (Lempainen 
et al., 2009). The principle of one surgical procedure published for this condition 
involves partial tenotomy of the diseased semimembranosus tendon to reduce its 
thickness (Figure 7). The sciatic nerve is also examined and any adhesions 
present are released (Lempainen et al., 2009).  
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Figure 7: Illustration of Surgical Procedure for Proximal Hamstring Tendinopathy: (A) The 
biceps femoris muscle is moved aside to expose semimembranosus tendon. (B) Partial tenotomy 
is performed on the tendinous portion of the semimembranous muscle. Additionally, the sciatic 
nerve is investigated to expose potential adhesions (C) The head of the semimembranosus tendon 
is attached to the biceps femoris tendon to prevent excess retraction. Figure taken from 
Lempainen et al., 2009 
 
Wound Healing:  
The wound healing cascade is an intricate and complex process. Three phases 
have been described: (1) the inflammatory phase, (2) the proliferative phase, and 
(3) the maturation and/or remodeling phase (Lee et al., 2011; Nguyen et al. , 2011) 
(Figure 8). The initial phase, the inflammatory phase, occurs in the first week 
after injury and involves hemostasis and recruitment of inflammatory mediators. 
An important part of the inflammatory process involves macrophages and 
fibroblasts, which are attracted in part by specific growth factors. The production 
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of these growth factors is stimulated in the process of repair and remains active 
during the healing stages (Nguyen et al., 2011).  
 
 
Figure 8: Wound healing cascade.  Figure demonstrates the healing cascade including the 
inflammation, proliferation, and remodeling phases. Figure taken from Nguyen et al., 2011 
 
15 
 
Regenerative Injection Therapy: 
In recent years, the injection of endogenous substances to treat acute and chronic 
injuries has become a topic of great interest and research. The aim of this 
treatment is to inject growth factors or other substances with regenerative 
properties into the injury site in order to stimulate a more vigorous healing 
response and to promote growth and repair of normal cells and tissue.  The term 
“prolotherapy”, which was coined by Hackett in 1950, was originally the general 
term to describe this type of treatments, but now it is known as regenerative 
injection therapy (RIT) (Fullerton & Reeves, 2010; Topol & Reeves, 2008). Many 
different substances have been used including: dextrose, osmotic fluids, irritants, 
particulates, or chemotactic agents, as well as concentrated autologous blood and 
platelet rich plasma (PRP). It is thought that healing is achieved through the 
formation of new collagen fibers through the induction of inflammation after 
injection (Banks, 1991). In addition to the injected substances, the act of needling 
which is also known as either tenotomy or fenestration, has also been shown to 
be an active process in healing (Yelland et al., 2004), although its exact role in 
tissue healing is still a subject of intense research.  
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Platelet-Rich Plasma: 
Concentrated platelet therapy, or Platelet-Rich Plasma has been in use for around 
20 years, but it was not until the New York Times reported PRP playing a 
deciding factor in the return to play of Pittsburgh Steeler player Hines Ward just 
in time for the 2009 Super bowl, did the treatment start to gain more widespread 
popular interest and attention (Lee et al., 2011; Schwarz, 2009). Although some 
studies have shown the potential efficacy of PRP injections in treating acute and 
chronic musculoskeletal injuries, such as rotator cuff surgery, elbow tendinosis, 
patellar tendinosis, and Achilles tendon injuries there remain many questions as 
to the mode of action, preparation, timing, and other factors involved in its 
clinical use (Taylor et al., 2011).  
 
Proposed Mechanism of Action  
The main rationale behind the use of platelet enriched plasma is two-fold: 1) 
Platelets are an essential part of the healing cascade and 2) Plasma contains a 
number of growth factors believed to be involved in healing and the 
inflammatory response.  
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Platelets are non-nucleated bodies in the blood that are essential to hemostasis. 
They contain three types of granules one of which is the alpha-granules.  Alpha 
granules contain a variety of proteins, cytokines, and other bioactive products, 
which are responsible for stimulating and regulating the process of wound 
healing (Table 1). The release of certain growth factors from these -granules aids 
the process of tissue regeneration (Foster et al., 2009).   
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TABLE 1: Growth Factors Identified Within Platelet-Rich Plasma and Their Physiologic Effect 
 
PD-EGF, platelet-derived epidermal growth factor; PDGF, platelet-derived growth factor; BMP, 
bone morphogenetic protein; TGF, transforming growth factor; IGF, insulin-like growth factor; 
VEGF, vascular endothelial growth factor; ECGF, endothelial cell growth factor; bFGF, basic 
fibroblast growth factor. Table adapted from Foster et al., 2009. 
 
Factor  
 
Target Cell/Tissue 
 
Function 
 
 
PD-EGF  
 
 
 
Blood vessel cells, outer skin 
cells 
Fibroblasts, and many other cell 
types  
 
 
Cell growth, recruitment  
Differentiation, skin closure 
Cytokine secretion 
 
PDGF A + B  
 
 
 
 
 
 
Fibroblasts, smooth muscle cells, 
chondrocytes, osteoblasts, 
mesenchymal stem cells  
 
 
 
 
Potent cell growth, recruitment 
Blood vessel growth, granulation 
Growth factor secretion; matrix 
formation with BMPs 
(collagen and bone) 
 
TGF-β1  
 
 
 
 
Blood vessel tissue, outer skin 
cells  
Fibroblasts, monocytes  
TGF gene family includes the 
BMPs  
Osteoblasts—highest levels of 
TGF-βr 
 
Blood vessel (±), collagen synthesis  
Growth inhibition, apoptosis (cell 
death) Differentiation, activation 
 
 
 
IGF-I, II  
 
 
 
Bone, blood vessel, skin, other 
tissues 
Fibroblasts  
 
 
Cell growth, differentiation, 
recruitment 
Collagen synthesis with PDGF 
 
 
VEGF, ECGF 
 
 
 
Blood vessel cells 
 
Cell growth, migration, new blood 
vessel growth 
Anti-apoptosis (anti–cell death)  
 
bFGF  
 
Blood vessels, smooth muscle, 
skin 
Fibroblasts, other cell types 
 
Cell growth 
Cell migration, blood vessel growth 
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It is theorized that the presence of increased a-granule may lead to inhibition of 
excess inflammation along with stimulation of stem cell proliferation and 
maturation (Paoloni, De Vos, Hamilton, Murrell, & Orchard, 2011). The platelet 
concentrate seems to modify the natural healing pathway by providing increased 
concentrations of growth factors and bioactive proteins which in turn stimulates 
regeneration of tissue with low baseline healing potential, resembling the initial 
stage of inflammation, and the attraction of leukocytes to the site of injury 
(Taylor et al., 2011). In vivo and animal studies have shown PRP addition 
resulted in cell proliferation, collagen deposition, improved gene expression, 
accelerated remodeling and angiogenic processes, increased anti-inflammatory 
response, increased fibrillogenesis, and improved collagen matrix (De Vos et al., 
2010). PRP also contains fibrin, fibronectin, and vitronectin, proteins important 
for cell adhesion, osteoconduction and as a matrix for bone, connective tissue, 
and epithelial migration (Marx, 2004). In addition to the PRP adjuvant, studies 
suggest that the act of injection is akin to tenotomy, which itself may have a 
component in the healing process due to induced local inflammation and local 
bleeding (Yelland et al., 2004).  
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Preparation and Administration 
At the present, there exists little consistency in regards to the preparation and 
administration of PRP. Taylor and colleagues (Taylor et al., 2011) noted the lack 
of standardized protocol in their review of PRP injections for tendon and 
ligament injuries. Researchers and clinicians report varied concentrations of PRP, 
timing of injection relative to preparation, activation of platelets, and other 
factors. The majority of preparations were in the form of an aqueous solution, 
but may include solid substance such as fibrin membranes, fibrin matrices, PRP 
gels, and the combinations thereof.  Platelet concentrations range from 6X10^3 to 
6x10^6 (per microliter plasma) after centrifugation (Taylor et al., 2011), while 
another study has suggested the effective concentration to be between 300,000-
1,000,000 per microliter (Pietrzak & Eppley, 2005). The average baseline 
concentration is about 200,000 per microliter of plasma and studies have reported 
the minimum increase in concentration to be 1,000,000 platelets per microliter, or 
about 4-5 times baseline platelet count (Marx, 2004).  
 
The preparation of PRP involves separating the cellular component from the 
plasma using centrifuges.  After the blood is drawn from the patient, the blood is 
then treated with an anti-coagulant and spun down resulting in a top layer of 
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plasma, middle layer of platelets and leukocytes, and bottom layer of red blood 
cells (Figure 9). Two rounds of centrifugation are often performed in order to 
concentrate the platelets and to separate out unnecessary components of whole 
blood (i.e. red blood cells, leukocytes) in order to reduce the risk of immune 
reactions. An additional  round of centrifugation is usually performed to 
separate the Platelet-poor Plasma (PPP) from the PRP  (Paoloni et al., 2011).  
 
 
 
Figure 9: Preparation of Platelet-Rich Plasma from Autologous Whole Blood. Figure taken 
from Nguyen et al., 2011 
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PRP Costs  
Currently, due to its investigational nature, PRP injections are generally not 
covered by insurance plans. Depending on the manufacturer, centrifuge used, 
and the amount of PRP needed, the cost of a PRP kit ranges from $140-$400. 
Adding costs of facilities, physician costs, and the cost of the injection procedure, 
totaling around $750-$2000, PRP may lead to significant cost out-of-pocket for 
most patients. However, although this may seem pricey, some investigators 
argue that effective PRP treatments are still much more cost-effective than the 
typical cost of surgery ($10,000-$15,000) (Nguyen et al., 2011).  
 
Side Effects  
Side effects of PRP are minimal and the most commonly reported include pain at 
the site of the injection, inflammation, and stiffness. One review by Paoloni et al., 
2011 reported side effect rates between 1-10% with average pain and stiffness of 
6.1 out of 10 lasting between 1.5 to 2.4 days.  
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Specific Aims 
 
PRP has shown a great deal of promise regarding its utility in treating a myriad 
of orthopedic issues, particularly tendon and ligament injuries. Currently, to the 
best of our knowledge, there exists only one study reporting the effects of 
injecting PRP into patients with high hamstring tendinopathy (Mautner et al., 
2013). Based on previously reported results in treating other chronic 
tendinopathies, we believe that similar results may be expected in treating the 
hamstrings with PRP.  
 
We will examine patient reported data on pre- and post- PRP injection surveys 
regarding pain levels, activities affected, prior treatments, etc., using these 
answers as evidence of the degree of recovery achieved in each patient. We will 
then compile the data and compute valuable statistics to describe the effects of 
the treatments.  
 
This study hopes to show that patients experiencing chronic symptoms of high 
hamstring tendinopathy, having attempted and failed physical therapy, will 
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show significant improvement in their pain levels and activity levels post-
treatment.  
In addition, we hope to learn about any additional correlations between patient 
history and clinical outcomes that may be relevant to future treatment guidelines 
and potentially create future research endeavors.  
25 
 
Methods 
 
Population:  
Patients were recruited for this study through a musculoskeletal/pain clinic in a 
community medical center. The primary patient populations seen at this 
institution includes both elite collegiate level athletes as well as community 
recreational athletes of various fitness levels. All patients had been referred by 
their physicians to receive PRP injections for the treatment of their tendinopathy 
and must meet the predetermined inclusion/exclusion criteria. The inclusion 
criteria include: at least 18 years of age, failing physical therapy, have positive 
MRI signs of high hamstring tendinopathy with or without adjacent bone 
marrow edema, and have at least one of the following positive clinical findings 
such as tender to palpation at the site of the ischial tuberosity, positive bent knee 
stretch test, positive supine plank test, positive prone resisted knee flexion or 
positive prone resisted hip extension.   The exclusion criteria for this study 
include the presence of other acute injuries to the lower limb, concurrent 
pregnancy, minors, or the presence of malignant disease.  
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Patients meeting the inclusion criteria without exclusion criteria were 
approached and recruited.  Additional information was gathered for complete 
baseline evaluation, including a Lower Extremity Functional Scale questionnaire 
(Binkley, Stratford, Lott, & Riddle, 1999) (Appendix 1). Patients were then 
scheduled for a PRP injection at either one of the two clinical sites. Patients then 
received a single percutaneous PRP injection prepared and administered 
according the study protocol parameters described in the following sections.  
 
PRP Preparation: 
PRP was prepared using the BioMet System.  Antecubital venipuncture was used 
to draw approximately 60 cmL of the patient's blood, followed by centrifugation 
for 15 min, yielding approximately 6-8 mL of PRP, which was then transferred to 
a sterile 12 ml syringe.  Sodium bicarbonate (8.4%) was added as a buffer to the 
PRP at a concentration of 0.05% to match the pH of the tendon tissue, in order to 
reduce potential patient discomfort.  
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Ultrasound Procedure: 
The patient is placed on the examination in prone position, and the gluteal 
regions were examined under ultrasound. The proximal hamstring tendon origin 
was identified by transverse and longitudinal scanning using a high frequency 
transducer (GE HealthCare Logic 9, UK). Local blood vessels and the sciatic 
nerve were identified. After identifying the target, a 21 gauge, 1.5 inch needle  
was guided to the target in a in-plane approach towards the hamstring tendons 
for injection of local anesthetic with 1% lidocaine.  Subsequently, the area was 
anesthetized with approximately 5 cc of 0.5% bupivicaine.   
 
Tenotomy and PRP Injection: 
In thin patients, the hamstring tendons may be reachable with the 21 gauge, 1.5 
inch needle used for anesthesia. In larger patients, a longer spinal needle is 
inserted into the proximal tendons under direct ultrasound guidance. Further 
anesthetic is then injected at the tendon/bone interface. This procedure is done 
while the PRP is being prepared in the centrifuge. The PRP is injected slowly 
under US guidance, targeting areas of focal hypoechoic echotexture or areas of 
partial tearing.  Injection is performed during gentle advance and retraction of 
the needle, in order to deposit the PRP deep, interstitial, and superficial to the 
28 
 
tendons. Typically, 5 passes of the needle through different areas of the tendons 
are used for needle tenotomy. In addition to tenotomy, the spinal needle is used 
to probe the ischial tuberosity itself, with the aim of stimulating the periosteum 
or releasing marrow factors, though the bone is typically very firm and the 
marrow space is not entered directly.  Post PRP injection, mild pressure is 
applied to the site to distribute the injected materials further about the hamstring 
tendons and to minimize any local bleeding.  Patients are kept prone for an 
additional 10 minutes following the procedure.   
 
Post-Treatment Protocol:  
Following injection, all patients were asked to observe a 1 week rest period with 
non-weight bearing for first 2 days, then progressive weight bearing using 
crutches advanced through the remainder of the week. After the first week, 
patients began physical therapy per protocol (Table 3).   
 
All patients were asked to revisit the clinic for a reevaluation after the 12th week. 
Based on the clinical evaluation, a new MRI was recommended if the recovery 
level was not as expected. At this point, the patient may proceed to continue with 
a second PRP injection or elect to undergo surgery consultation.  
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Table 2: Post-injection Physical Therapy Protocol 
0-2 weeks 1) 2 days non-weight bearing lower extremity 
Walking assisted with crutches  
Ice allowed at the injection site 
 
2) Partial weight-bearing with crutches 
    Progressively increase weight-bearing as tolerated. 
    Ice, compress, elevate. AROM multiple times per day. 
2-4 weeks  Multi-planar isometrics and gentle passive stretching in 
addition to AROM 
May begin weight-bearing as tolerated in the lower 
extremity 
Continue edema control measures (i.e.: compression, ice, 
elevation) 
Stationary bike without resistance and no standing while 
biking. 
 
4 weeks  Begin gentle isotonics 
May add resistance to bike but no standing 
May begin elliptical machine. 
6 weeks   Begin eccentric protocol 
May transition to treadmill 
Begin with walking and progress to jogging over next 
couple of weeks  
10 weeks Begin plyometrics, sports specific drills. 
12 weeks Begin plyometrics, sports specific drills. 
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Statistical Analysis:  
We defined patients with “significant improvement” as those whose LEFS 
increase by at least 9 points, according to the standards of the authors outlining 
the assessment (Binkley et al., 1999).  
 
 
 
 
 
 
31 
 
Results 
 
At the time of this paper, 15 PRP injections had been performed. Only 3 patients 
declined to participate in the study. Of the remaining 12 participants, 3 were 
excluded due to the lack of the completion of the initial LEFS questionnaire, 1 
due to a lack of 12 week follow-up evaluation, and 1 for not meeting the 
inclusion criterion of having attempted and failed physical therapy.  As a result, 
7 total patients were included in the analysis. The mean age of included patients 
was 48.4 years with the majority being female (5/7, or 71.4%). 1 patient reported 
complete resolution of pain at rest. 2 out of 7, or 62.5%, reported duration of their 
symptoms as greater than 6 months, and 3 out of 8 (37.5%) reporting symptoms 
persisting for one year or more. All patients in this study had undergone and 
failed physical therapy. Many reported additional treatments including NSAID’s 
(4/7, or 57.1%), corticosteroid injections (7/7 or 100%), and other alternative and 
complementary treatments such as acupuncture or massage (4/7, or 57.1%). The 
patient characteristics are summarized in Table 3.  
 
The average LEFS for patients pre-treatment was 47.7, ranging from 11-67. The 
average maximal function percentage was 59.6%, ranging from 13.8%-83.8%. On 
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12 weeks post-treatment follow-up, the LEFS average increased to 65.0, ranging 
from 49-75. Maximal function post-treatment was 81.3%, ranging from 61.3%-
100%. This corresponds to an average increase in LEFS and Maximal Function of 
17.3 units and 21.6%, respectively. The difference was not statistically significant 
due to the small sample size. Clinical outcomes are summarized in Table 4.  
 
Table 3: Patient Characteristics and Prior Treatments 
 
Characteristic  
 
Number of Patients (%) 
 
Age  
     18-30 
     31-60 
     >61 
 
Gender  
     Female  
     Male 
      
 
Prior Treatments 
     NSAID’s  
     Physical Therapy 
     Steroid Injections 
     Other 
 
 
 
2(28.6%) 
3(42.9%) 
2(28.6%) 
 
 
5(71.4%) 
2(28.6%) 
 
 
 
4(57.1%) 
7(100%) 
7(100%) 
4(57.1%) 
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Table 4: Clinical Outcomes for 8 of 15 Patients Receiving PRP Injections 
 
 
Characteristic 
 
Number of Patients (%) 
 
 
Duration of Symptoms Prior to Injection 
     >6 months 
     6 months to 1 year 
     >1 year 
 
Degree of LEFS improvement 
 
     Significant (Difference >9) 
     Moderate (Difference > 0) 
     None (Difference < 0)  
 
Degree of At Rest Pain Resolution  
 
     >50%  
     0% < x < 50% 
     <0% 
 
Degree of Maximum Pain Resolution  
 
     ≥50%  
     0% < x < 50% 
     <0% 
 
 
 
2(28.6%) 
2(28.6%) 
3(42.9%) 
 
 
 
 
3(42.9%) 
2(28.6%) 
2(28.6%) 
 
 
 
3(42.9%) 
2(28.6%) 
2(28.6%) 
 
 
 
1(14.3%) 
4(57.1%) 
2(28.6%) 
 
 
 
34 
 
DISCUSSION 
 
Platelet-rich plasma has recently gained widespread attention (Schwarz, 2009), 
despite its use for over 20 years. Although there have been a number of studies 
regarding its use, there is little consensus regarding its indications, preparation 
method of delivery, and efficacy (Foster et al., 2009; Taylor et al., 2011). At the 
present, there have been no studies reported on the use of PRP in treating high 
hamstring tendinopathy. The patients included in this study were recommended 
to undergo PRP injections by their treating physicians due to their lack of 
response to eccentric hamstring training with physical therapy and corticosteroid 
injection. Eccentric strengthening is considered as the gold standard for chronic 
tendinopathy.  
 
Many of the patients included reported significant improvements in their 
symptoms and overall athletic capabilities, while a smaller percentage reported 
no benefit from the treatment or even a lower LEFS. An increase in LEFS greater 
than 9 is suggestive of significant improvement (Binkley et al., 1999). Although 
we see an average LEFS difference in 18.9 in this study (much greater than 9), 
these improvements did not achieve statistical significance (P=0.076) due to the 
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lack of statistical power secondary to the small sample size. As many as 50% of 
patients experienced both significant reductions in at rest pain levels as well as 
significant improvement in LEFS, with multiple patients reporting complete 
resolution in many activities on the LEFS.  
 
There were multiple limitations that potentially affected the outcomes of our 
research. First, the small sample size limited the statistical power of the study. 
Second, questionnaires can lead to subjective results, can be influenced by recall, 
and it is difficult to compare the results of one patient with another. Objective 
data regarding the effects of PRP on hamstring tendinopathy can be obtained 
through imaging studies such as MRI and ultrasound by comparing pre- and 
post- treatment images, but that would not necessarily correlate to patient 
symptoms or functional status. Third, the standard follow-up time was set at 12 
weeks, but it is possible that the healing timeline is highly variable and the full 
healing potential of PRP may take significantly longer for some patients. 
Currently, there are no clear guidelines of duration of treatment effect and 
follow-up timeline. Including follow-ups for times longer than 12 weeks may 
better demonstrate the long-term outcome of the PRP treatment. Lastly, given the 
retrospective study design, neither the patients nor the clinicians were blinded. 
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There were no controls besides historical control, which cannot rule out the 
influence of other confounding factors.   
 
Future Research 
Although not statistically significant, the results of this study do show promise 
for the use of PRP in treating high hamstring tendinopathy. Future studies with 
larger patient sample size sufficient to achieve statistical power can help 
determine the clinical effect seen in this study. Subgroup analysis with sufficient 
follow up may better delineate the onset and the duration of treatment benefit, 
the degrees of symptoms and functional improvement, and the demographic or 
biomechanical factors influencing them. Pre- and post-treatment imaging studies 
using MRI or ultrasound can help demonstrate the macroscopic tissue changes, 
which can then be correlated with symptoms and function. Lastly, randomized 
double-blind controlled study design should be conducted to remove the 
confounding factors involved. 
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Appendix 1: Patient Baseline Evaluation Form 
 
 
Injection date:                  
Age:                                                                        
Gender:     
Injection side:    Right / Left                                        
 
Allergies / Medical conditions: 
 
Sports performed (hours per week / mileage): 
 
Mechanism of injury:   Acute   Chronic    Previous injury 
 
Duration of hamstring symptoms:   
 
Prior treatments:     
AINSD         Physical Therapy        Steroid injections (nº__ )       Other  
Pain score (0-10): At rest__ Maximal pain__ 
Activities make pain worst:  
Ability to continue sports: Impact in patient’s sport life 
Pain with sprinting or accelerating. 0   1   2   3   4 
Pain running uphill/downhill.  0   1   2   3   4 
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Appendix 2: Low Extremity Functional Scale 
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